Ichiro Ogino1, Shigenobu Watanabe2, Kingo Hirasawa3, Toshihoro Misumi4, Masaharu Hata5, Chikara Kunisaki6. 1. Department of Radiation Oncology, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan ogino1ro@urahp.yokohama-cu.ac.jp. 2. Department of Radiation Oncology, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. 3. Division of Endoscopy, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. 4. Department of Biostatistics, Yokohama City University, Yokohama, Japan. 5. Division of Radiation Oncology, Department of Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 6. Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Abstract
AIM: To evaluate whether patients with T1 esophageal squamous cell carcinoma receiving definitive radiotherapy can be managed without concurrent chemotherapy, and the role of 18F-fluorodeoxyglucose positron-emission tomography with computed tomography (FDG-PET/CT) in demonstrating local control (LC). PATIENTS AND METHODS: Twenty-four out of 37 patients with newly-diagnosed T1 EC treated with definitive radiotherapy between July 2009 and July 2016 were retrospectively analyzed. FDG-PET/CT was performed before treatment. Eleven patients were assigned to a concurrent chemoradiotherapy (CRT) group. Thirteen were placed in a no-CRT group. The two groups were compared and univariate analysis of clinical factors influencing the prognosis in each group was conducted. RESULTS: Mean radiotherapy doses were 59.2 Gy in the no-CRT group and 55.5 Gy in the CRT group (p=0.025). Overall survival, disease-free survival, and LC rates at 2 years were lower in the no-CRT group compared to the CRT group. Disease-free survival and LC rates at 2 years were significantly lower in the patients with FDG-avid primary tumor in the no-CRT group (p=0.002 and p=0.002, respectively). All patients with FDG-avid primary tumors in the no-CRT group developed local recurrence. CONCLUSION: It is important to note that all patients with FDG-avid primary tumor in the no-CRT group developed local recurrence. This would suggest that concurrent chemotherapy is an integral part of disease management in patients with T1 esophageal squamous cell carcinoma. Copyright
AIM: To evaluate whether patients with T1 esophageal squamous cell carcinoma receiving definitive radiotherapy can be managed without concurrent chemotherapy, and the role of 18F-fluorodeoxyglucose positron-emission tomography with computed tomography (FDG-PET/CT) in demonstrating local control (LC). PATIENTS AND METHODS: Twenty-four out of 37 patients with newly-diagnosed T1 EC treated with definitive radiotherapy between July 2009 and July 2016 were retrospectively analyzed. FDG-PET/CT was performed before treatment. Eleven patients were assigned to a concurrent chemoradiotherapy (CRT) group. Thirteen were placed in a no-CRT group. The two groups were compared and univariate analysis of clinical factors influencing the prognosis in each group was conducted. RESULTS: Mean radiotherapy doses were 59.2 Gy in the no-CRT group and 55.5 Gy in the CRT group (p=0.025). Overall survival, disease-free survival, and LC rates at 2 years were lower in the no-CRT group compared to the CRT group. Disease-free survival and LC rates at 2 years were significantly lower in the patients with FDG-avid primary tumor in the no-CRT group (p=0.002 and p=0.002, respectively). All patients with FDG-avid primary tumors in the no-CRT group developed local recurrence. CONCLUSION: It is important to note that all patients with FDG-avid primary tumor in the no-CRT group developed local recurrence. This would suggest that concurrent chemotherapy is an integral part of disease management in patients with T1 esophageal squamous cell carcinoma. Copyright
Authors: T Mizumoto; T Hiyama; S Oka; N Yorita; K Kuroki; M Kurihara; Y Yoshifuku; Y Sanomura; Y Urabe; K Arihiro; S Tanaka; K Chayama Journal: Dis Esophagus Date: 2018-04-01 Impact factor: 3.429
Authors: J-B Clavier; D Antoni; D Atlani; M Ben Abdelghani; C Schumacher; P Dufour; J-E Kurtz; G Noel Journal: Dis Esophagus Date: 2012-10-26 Impact factor: 3.429
Authors: Paul M Jeene; Eva Versteijne; Mark I van Berge Henegouwen; Jacques J G H M Bergmann; Elisabeth D Geijsen; Hanneke W M van Laarhoven; Maarten C C M Hulshof Journal: Acta Oncol Date: 2016-11-15 Impact factor: 4.089
Authors: Jessica M Leers; Steven R DeMeester; Arzu Oezcelik; Nancy Klipfel; Shahin Ayazi; Emmanuele Abate; Jörg Zehetner; John C Lipham; Linda Chan; Jeffrey A Hagen; Tom R DeMeester Journal: Ann Surg Date: 2011-02 Impact factor: 12.969